{"id":131635,"date":"2025-11-12T19:17:06","date_gmt":"2025-11-12T19:17:06","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/131635\/"},"modified":"2025-11-12T19:17:06","modified_gmt":"2025-11-12T19:17:06","slug":"novo-nordisks-100-million-coramitug-shows-promise-in-reducing-heart-failure-biomarker-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/131635\/","title":{"rendered":"Novo Nordisk’s $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

In a presentation at the American Heart Association’s (AHA’s) 2025 Scientific Sessions, researchers on Tuesday shared data from Novo Nordisk A\/S’ (NYSE:NVO<\/a>) Coramitug Phase 2 trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM).<\/p>\n

Data<\/p>\n

The phase 2 trial showed<\/a> that coramitug, an antibody targeting misfolded transthyretin in ATTR-CM, was well tolerated.<\/p>\n

A dose of 60 mg\/kg resulted in a statistically significant reduction in NT-proBNP, a validated marker of disease progression, with no statistically significant effect on the six-minute walk test (6MWT) within 52 weeks.<\/p>\n

Also Read: Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance<\/a><\/p>\n

ATTR-CM is a progressive disease caused by the deposition of transthyretin as amyloid in the myocardium (the muscular tissue of the heart).<\/p>\n

Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis.<\/p>\n

Background<\/p>\n

Coramitug was initially developed by Prothena Corporation plc (NASDAQ:PRTA<\/a>) and was acquired by Novo Nordisk in July 2021.<\/p>\n

Under the terms of the agreement, Prothena is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones, including the $100 million earned to date<\/a>.<\/p>\n

Novo Nordisk recently initiated the Phase 3 CLEOPATTRA clinical trial evaluating the effects of coramitug versus placebo on cardiovascular outcomes in participants with ATTR-CM.<\/p>\n

Prothena is eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the CLEOPATTRA Phase 3 clinical trial.<\/p>\n

In total, 104 participants were randomized and dosed.<\/p>\n

90% of participants were on disease-modifying therapy; 84% were treated with Pfizer Inc.’s (NYSE:PFE<\/a>) Vyndaqel\/Vyndamax (tafamidis), and 7 with Alnylam Pharmaceuticals, Inc.’s (NASDAQ:ALNY<\/a>) TTR silencers (patisiran, n=4; vutrisiran, n=3).<\/p>\n

From baseline to week 52, coramitug 60 mg\/kg significantly reduced NT-proBNP levels compared with placebo (\u201348%, \u201322%).<\/p>\n

The change in 6MWT from baseline to week 52 was not statistically different from placebo with either dose. Coramitug 60 mg\/kg was associated with improved functional echocardiographic parameters and was well tolerated.<\/p>\n

Price Action: NVO stock is up 0.87% at $49.58 during the premarket session at the last check on Wednesday.<\/p>\n

Read Next:<\/p>\n

Photo by JHVEPhoto via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"In a presentation at the American Heart Association’s (AHA’s) 2025 Scientific Sessions, researchers on Tuesday shared data from…\n","protected":false},"author":2,"featured_media":131636,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[17835,17838,17837,17836,16303,18065,12224,134,527,111,139,69,12223,90601,17840,90602,90603,90604],"class_list":{"0":"post-131635","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-news","13":"tag-category-top-stories","14":"tag-cms-wordpress","15":"tag-health","16":"tag-healthcare","17":"tag-new-zealand","18":"tag-newzealand","19":"tag-nz","20":"tag-pageisbzpro-bz","21":"tag-symbol-alny","22":"tag-symbol-nvo","23":"tag-symbol-pfe","24":"tag-symbol-prta","25":"tag-tag-why-its-moving"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/131635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=131635"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/131635\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/131636"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=131635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=131635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=131635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}